Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, MD, USA.
Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, MD, USA.
Int J Pharm. 2018 Dec 20;553(1-2):441-453. doi: 10.1016/j.ijpharm.2018.10.066. Epub 2018 Oct 29.
The objective of the current study was to optimize for the first time the formulation variables of self-emulsified drug delivery system (SEDDS) based on drug solubilization during lipolysis under a biorelevant condition of digestion such as lipase activity, temperature, pH, fed-fasting state, etc. Nimodipine (ND), a BCS class II, was used as a model drug to prepare the SEDDS. Various oils, surfactants, and cosurfactants were screened for their solubilization potential of ND. Area of self-emulsification was identified using various ternary phase diagrams. Box-Behnken design was employed to investigate effects of formulation variables on various dispersion, emulsification, and lipolysis characteristics of SEDDS. Among 26 candidate formulations, highest ND solubility of 12.72%, 11.09% and 11.2% w/w were obtained in peppermint oil as the oily phase, Cremphor EL as the surfactant and PEG400 as the cosurfactant, respectively. Cremphor EL was the most significant factor to decrease SEDDS droplet size to 30.16 nm. On the other hand, increasing the oil concentration was found to significantly increase the polydispersity index up to 0.31. A faster emulsification rate of 3.37%/min was obtained at higher Cremphor El/PEG 400 ratio. Increasing the percentage of lipid components of SEDDS resulted in lower rate of lipolysis with less recovery of ND in aqueous phase. Under fed state, percentage of lipolysis of optimized formulation was less than that observed under fasted state. However, lowest rate and percentage of lipolysis were observed in lipolysis media without phospholipids and bile salts. Hence, this study demonstrated that in vitro lipolysis could be used as a surrogate approach to distinguish effects of formulation variables on fate of SEDDS upon digestion. Further studies are in progress to identify the lipolytic products of the employed excipients by LC-MS/MS.
本研究的目的是首次优化基于脂肪酶活性、温度、pH 值、进食-禁食状态等生物相关消化条件下的脂解过程中药物增溶作用的自乳化药物传递系统(SEDDS)的配方变量。尼莫地平(ND)作为一种 BCS 类 II 药物,被用作制备 SEDDS 的模型药物。筛选了各种油、表面活性剂和共溶剂,以评估其对 ND 的增溶潜力。使用各种三元相图确定自乳化区域。采用 Box-Behnken 设计研究配方变量对 SEDDS 各种分散、乳化和脂解特性的影响。在 26 种候选配方中,分别以薄荷油为油相、Cremphor EL 为表面活性剂、PEG400 为共溶剂,获得了最高的 ND 溶解度 12.72%、11.09%和 11.2%w/w。Cremphor EL 是降低 SEDDS 粒径至 30.16nm 的最显著因素。另一方面,增加油浓度被发现显著增加了多分散指数至 0.31。在更高的 Cremphor El/PEG 400 比例下,乳化速度更快,达到 3.37%/min。SEDDS 中脂质成分的百分比增加导致脂解速度降低,水相中的 ND 回收率降低。在进食状态下,优化配方的脂解百分比小于禁食状态下观察到的百分比。然而,在没有磷脂和胆汁盐的脂解介质中,观察到最低的脂解速率和百分比。因此,本研究表明,体外脂解可以作为一种替代方法,用于区分配方变量对 SEDDS 在消化过程中命运的影响。正在进行进一步的研究,以通过 LC-MS/MS 鉴定所使用赋形剂的脂解产物。